ArticleCureus2025
De Novo Myeloid Sarcoma of the Kidney: A Case Report and Literature Review of Clinical Features and Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS) can manifest as a primary disease entity, known as de novo myeloid sarcoma, without the concurrent presence of acute or chronic myelocytic leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm. It is crucial to approach suspected de novo myeloid sarcoma cases comprehensively to prevent misdiagnosis and ensure timely and accurate treatment. We report a case of de novo myeloid sarcoma involving the kidney in a 38-year-old female patient with a chief complaint of a rapidly enlarging palpable mass in the upper right quadrant for over a month. The patient's enhanced abdominal CT scan result was initially suspected to be renal cell carcinoma. Subsequently, we performed radical nephrectomy and post-operative pathology, immunohistochemistry, and cytogenetic analysis to confirm the diagnosis of de novo myeloid sarcoma. Histopathological analysis confirmed malignancy originating from the right kidney, accompanied by necrosis. The tumor cells displayed moderate size, evident pleomorphism, and off-centered granular cytoplasm. Extensive infiltration of the renal parenchyma was observed, involving the renal capsule, perirenal adipose tissue, and renal pelvis mucosa. CD117 displayed positive immunohistochemical staining. There is currently a dearth of studies that comprehensively describe de novo myeloid sarcoma involving the urogenital tract. In light of this gap in the literature, the present study aims to provide a systematic literature review and present a case of de novo myeloid sarcoma involving the kidney in patients with normal bone marrow biopsy. Our objective is to elucidate the clinical presentation and prognosis of de novo myeloid sarcoma involving the urogenital tract, thereby contributing to the existing knowledge base, and facilitating evidence-based treatment decisions. The multifaceted nature of MS necessitates a multidisciplinary approach, including thorough diagnostic evaluation involving immunohistochemistry, cytochemistry, and cytogenetic analysis. Standardizing terminology and refining diagnostic and treatment algorithms through future prospective studies are vital steps toward enhancing clinical management and prognosis for patients with de novo myeloid sarcoma of the urogenital tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.